Cargando…

Role of MicroRNAs in Pathophysiology of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder worldwide. It includes wide range of diseases from different subtypes of simple steatosis to non-alcoholic steatohepatitis (NASH), which may be complicated by liver fibrosis, cirrhosis, or hepatocellular carcinoma. Of the ep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iravani, Farzaneh, Hosseini, Neda, Mojarrad, Majid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Iranian Association of Gastroerterology and Hepatology 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488503/ https://www.ncbi.nlm.nih.gov/pubmed/31049168 http://dx.doi.org/10.15171/mejdd.2018.113

Ejemplares similares

Non-alcoholic Fatty Liver Disease and Steatohepatitis: Risk Factors and Pathophysiology
por: Akter, Sharmin
Publicado: (2022)

Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review
por: Kan Changez, Mah I, et al.
Publicado: (2023)

Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease
por: Torres, Jorge-Luis, et al.
Publicado: (2018)

Decoding the Pathophysiology of Non-alcoholic Fatty Liver Disease Progressing to Non-alcoholic Steatohepatitis: A Systematic Review
por: Yaqub, Sayma, et al.
Publicado: (2021)

MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives
por: Hochreuter, Mette Yde, et al.
Publicado: (2022)

Immunological Mechanisms in the Pathophysiology of Non-Alcoholic Steatohepatitis
por: Vonghia, Luisa, et al.
Publicado: (2013)

An Animal Model for the Juvenile Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
por: Marin, Veronica, et al.
Publicado: (2016)

Long Non-Coding RNAs Involved in Progression of Non-Alcoholic Fatty Liver Disease to Steatohepatitis
por: Atanasovska, Biljana, et al.
Publicado: (2021)

Pathophysiology of Non Alcoholic Fatty Liver Disease
por: Petta, Salvatore, et al.
Publicado: (2016)

Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
por: Dowman, J K, et al.
Publicado: (2011)

Pleiotropic Effects of Statins in the Light of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
por: Ahsan, Farah, et al.
Publicado: (2020)

Using intestinal flora to distinguish non-alcoholic steatohepatitis from non-alcoholic fatty liver
por: Li, Chao, et al.
Publicado: (2020)

Machine learning to predict progression of non‐alcoholic fatty liver to non‐alcoholic steatohepatitis or fibrosis
por: Ghandian, Sina, et al.
Publicado: (2022)

Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis
por: Becker, Philip P., et al.
Publicado: (2015)

Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease
por: Daher, Saleh, et al.
Publicado: (2018)

Multiparametric MR Index for the Diagnosis of Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease
por: Kim, Jeong Woo, et al.
Publicado: (2020)

Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
por: Hattori, Sachiko, et al.
Publicado: (2021)

Identification of Autophagy-Related Genes in the Progression from Non-Alcoholic Fatty Liver to Non-Alcoholic Steatohepatitis
por: Ma, Mengyao, et al.
Publicado: (2021)

Liver Fibrogenesis in Non-Alcoholic Steatohepatitis
por: Bian, Zhaolian, et al.
Publicado: (2012)

Circulating MicroRNAs in Patients with Chronic Hepatitis C and Non-Alcoholic Fatty Liver Disease
por: Cermelli, Silvia, et al.
Publicado: (2011)

Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma
por: Afonso, Marta B., et al.
Publicado: (2016)

Epidemiology of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in Japan: A focused literature review
por: Eguchi, Yuichiro, et al.
Publicado: (2020)

A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis
por: Ganguli, Surosree, et al.
Publicado: (2019)

Hypoxia-Inducible Factors as Key Players in the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
por: Holzner, Lorenz M. W., et al.
Publicado: (2021)

Activation and Functional Priming of Blood Neutrophils in Non-Alcoholic Fatty Liver Disease Increases in Non-Alcoholic Steatohepatitis
por: Lauszus, Johanne Sloth, et al.
Publicado: (2021)

Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis
por: Baker, Susan S., et al.
Publicado: (2010)

Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention
por: Tacke, Frank, et al.
Publicado: (2021)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

The Target MicroRNAs and Potential Underlying Mechanisms of Yiqi-Bushen-Tiaozhi Recipe against‐Non-Alcoholic Steatohepatitis
por: Hong, Wei, et al.
Publicado: (2020)

Metabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseases
por: Safaei, Akram, et al.
Publicado: (2016)

Myosteatosis rather than sarcopenia associates with non‐alcoholic steatohepatitis in non‐alcoholic fatty liver disease preclinical models
por: Nachit, Maxime, et al.
Publicado: (2020)

Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update
por: Di Pasqua, Laura Giuseppina, et al.
Publicado: (2022)

The comparison of resting metabolic rate between biopsy-proven non-alcoholic steatohepatitis and non-alcoholic fatty liver patients
por: Kenger, Emre Batuhan, et al.
Publicado: (2020)

Transcriptional and Epigenetic Alterations in the Progression of Non-Alcoholic Fatty Liver Disease and Biomarkers Helping to Diagnose Non-Alcoholic Steatohepatitis
por: Zhu, Yalan, et al.
Publicado: (2023)

Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease
por: Gallego-Durán, Rocío, et al.
Publicado: (2016)

Correlation between Fibroscan and laboratory tests in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients for assessing liver fibrosis
por: Al Danaf, Layal, et al.
Publicado: (2022)

Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice
por: López-Pastor, Andrea R., et al.
Publicado: (2021)

S100A9: A Potential Biomarker for the Progression of Non-Alcoholic Fatty Liver Disease and the Diagnosis of Non-Alcoholic Steatohepatitis
por: Liu, Xiaolin, et al.
Publicado: (2015)

Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma
por: Ocker, Matthias
Publicado: (2020)

Longitudinal analysis of a dietary mouse model of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
por: Saenz, Marissa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bn8e91u8ejc3093vf89h2immg0